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Assembly factors play a critical
role in the biogenesis of mito-
chondrial respiratory chain com-
plexes, some of which are pres-
ent in large structures known as
supercomplexes. Various assem-
bly factors have been proposed
as required for supercomplex
assembly, including HIGD2A. We
used quantitative proteomics
and gene editing to clarify the
function of human HIGD2A, re-
vealing it to be a classical as-
sembly factor required for bio-
genesis of mitochondrial DNA




• Quantitative proteomics reveals HIGD2A is required for assembly of the COX3 module.
• Pulse-SILAC demonstrates that HIGD2A is involved in COX3 biogenesis.
• Supercomplexes in HIGD2A knockout cells are depleted of COX3.
• HIGD2A is the first assembly factor identified for the COX3 module of Complex IV.
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HIGD2A is Required for Assembly of the COX3
Module of Human Mitochondrial Complex IV
Daniella H. Hock1x , Boris Reljic1, Ching-Seng Ang2, Linden Muellner-Wong1,
Hayley S. Mountford3,4, Alison G. Compton3,4, Michael T. Ryan5x,
David R. Thorburn3,4,6, and David A. Stroud1,*x
Assembly factors play a critical role in the biogenesis of
mitochondrial respiratory chain complexes I-IV where
they assist in the membrane insertion of subunits, attach-
ment of co-factors, and stabilization of assembly interme-
diates. The major fraction of complexes I, III and IV are
present together in large molecular structures known as
respiratory chain supercomplexes. Several assembly fac-
tors have been proposed as required for supercomplex
assembly, including the hypoxia inducible gene 1 domain
family member HIGD2A. Using gene-edited human cell
lines and extensive steady state, translation and affinity
enrichment proteomics techniques we show that loss of
HIGD2A leads to defects in the de novo biogenesis of
mtDNA-encoded COX3, subsequent accumulation of com-
plex IV intermediates and turnover of COX3 partner pro-
teins. Deletion of HIGD2A also leads to defective complex
IV activity. The impact of HIGD2A loss on complex IV was
not altered by growth under hypoxic conditions, consis-
tent with its role being in basal complex IV assembly.
Although in the absence of HIGD2A we show that mito-
chondria do contain an altered supercomplex assembly,
we demonstrate it to harbor a crippled complex IV lacking
COX3. Our results redefine HIGD2A as a classical assem-
bly factor required for building the COX3 module of com-
plex IV.
The electron transport chain (ETC) of human mitochondria
is comprised of four multiprotein complexes (Complex I-IV)
embedded in the inner mitochondrial membrane (IMM). In a
process known as oxidative phosphorylation the ETC takes
electrons from metabolites and uses their energy to build a
proton gradient across the IMM, which in turn powers pro-
duction of ATP through complex V (F1Fo ATP Synthase).
Complex IV (CIV; CcO; cytochrome c oxidase) is the fourth
and last enzyme of the ETC and catalyzes the transfer of
electrons from cytochrome c to molecular oxygen. Com-
plexes I, III, and IV have been shown to exist in several higher
order structures known as respiratory chain supercomplexes
or respirasomes (1–4). These structures have been suggested
to reduce production of reactive oxygen species (ROS), im-
prove complex stability and/or distribution throughout the
protein dense environment of the IMM, and allow efficient
channeling of substrates (3–8).
Complex IV is composed of 14 different subunits of dual
genetic origin, the core membrane embedded subunits,
COX1, COX2, and COX3 are encoded by mitochondria DNA
(mtDNA) genes MT-CO1, MT-CO2, and MT-CO3, that are
translated on mitochondrial ribosomes in the matrix, whereas
the remaining 11 subunits are encoded by nuclear DNA,
translated in the cytosol and imported into the mitochondria
where they assemble with mtDNA encoded subunits. Nuclear
encoded subunits can therefore be grouped into assembly
modules seeded by each of the mtDNA encoded subunits
(Fig. 1) (9, 10). During complex IV biogenesis, redox active
heme and copper cofactors are incorporated into COX1 and
COX2, which together with COX3 form the conserved core of
the enzyme. Although COX3 does not have a direct role in
electron transport, it is thought to play a regulatory role in
modulating complex IV activity (11, 12). Homologs of COX3
are present in complex IV throughout the tree of life (13) and
mutations within MT-CO3 lead to complex IV deficiency and
mitochondrial encephalopathy or myopathy (MIM 516050)
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(14, 15) implicating the importance of COX3 in complex IV and
mitochondrial function.
Biogenesis of complex IV occurs through the coordinated
effort of more than 30 known assembly factors with roles
including control of mitochondrial RNA stability and transla-
tion, membrane insertion of mtDNA encoded subunits, cop-
per and heme biosynthesis and loading and stabilization of
subunit modules during assembly (9, 10, 16). Although several
assembly factors are known to be essential for stabilizing the
modules containing COX1 and COX2, to date no assembly
factors have been associated with the COX3 module (contain-
ing COX3, COX6A, COX6B, and COX7A) in humans. Two
assembly factors have also been suggested to support
complex IV-containing supercomplex assembly, COX7A2L
(SCAFI) and hypoxia inducible gene 1 domain family member
HIGD2A (17). COX7A2L was originally shown to be present
within the supercomplex but not in the holo form of complex
IV (6). A mouse strain harboring a truncated form of the protein
lacked some forms of the supercomplexes and exhibited
altered mitochondrial respiration, leading the authors to sug-
gest the protein is required for supercomplex stability (6).
Several studies have disputed this finding (18–23) and it is
now understood that COX7A2L plays a role as a checkpoint
for assembly of CIII2 into the supercomplex (17), a result that
explains the differences in supercomplex distribution ob-
served in mitochondria lacking full length COX7A2L. Yeast (S.
cerevisiae) homologs of HIGD2A (Rcf1 and Rcf2) belong to the
hypoxia inducible gene 1 domain containing (HIGD) family and
were originally suggested to be required for assembly and
stability of the yeast CIII2/IV supercomplex (24–26). Deletion
of Rcf1 leads to impaired assembly of Cox12 and Cox13
(COX6B and COX6A in humans) into complex IV, reduced
association with Rcf2, and a reduction in the levels CIII2/IV
supercomplex (24–26). Recent studies have suggested a reg-
ulatory role for Rcf1 and Rcf2 in complex IV activity (27)
through association with complex IV intermediates (28). In-
vestigation into the function of mammalian homologs HIGD1A
and HIGD2A have been limited to only a few studies. Both
HIGD1A and HIGD2A were originally identified in a screen for
genes up-regulated during HIF1 dependent hypoxia (29, 30).
Following discovery of Rcf1 and Rcf2 in yeast supercomplex
assembly, Chen et al. (26) showed that knockdown of Higd1a
in mouse myoblasts had no impact on respiratory chain su-
percomplexes whereas, knockdown of Higd2a led to reduced
amounts of CIII2/CIV and a higher-order assembly now known
to be the respiratory chain megacomplex (CI2/III2/IV2) (2). No
impact was observed on the levels of holo complex IV, leading
the authors to suggest Higd2a is a supercomplex assembly
factor, consistent with the studies in yeast (26). In contrast,
HIGD1A has recently been suggested to associate non-stoi-
chiometrically with an early assembly intermediate consisting
of COX1 and associated subunits (10) and induce structural
changes around the heme a active center altering complex IV
activity during hypoxic stress (31).
We identified HIGD2A as a protein strongly up-regulated in
lymphoblasts from a patient with ETC complex IV deficiency.
Given that the yeast homolog of HIGD2A has been previously
associated with either complex IV or respiratory chain super-
complex assembly, we aimed to clarify the function of human
HIGD2A as well as its ortholog HIGD1A. Using CRISPR/Cas9
generated knockout cell lines we show that loss of HIGD1A
leads to a modest defect in mitochondrial oxygen consump-
tion and stability of subunits present within the COX1 module
but does not affect complex assembly. Although we find
HIGD1A is indeed induced during hypoxia, this results in no
apparent changes to complex IV or supercomplex assembly.
Conversely, we demonstrate that loss of HIGD2A leads to a
strong defect in mitochondrial respiration, complex IV assem-
bly and activity because of impaired biogenesis of newly
translated COX3, and subsequent degradation of nuclear en-
coded subunits present within the COX3 module. We con-
clude that HIGD2A is a classical assembly factor involved in
the early steps of COX3 biogenesis.
EXPERIMENTAL PROCEDURES
Tissue Culture and Generation of Cell Lines—HEK293T cell lines
were cultured in Dulbecco’s modified Eagle’s medium (DMEM High
Glucose) supplemented with 10% (v/v) fetal calf serum (FCS; CellSera,
Rutherford, NSW, Australia), penicillin/streptomycin (Thermo Fisher Sci-
entific, Scoresby, VIC, Australia) and 50 g ml1 uridine (Sigma-Aldrich,
North Ryde, NSW, Australia) at 37 °C under an atmosphere of 5% CO2.
Patient lymphoblasts were obtained with familial informed consent as
part of diagnostic investigations, and associated studies were ap-
proved by the Royal Children’s Hospital Institutional Review Board
(HREC reference number 34228). Early passage subclones of a
single lymphoblast clone derived from whole patient and control
FIG. 1. Human complex IV colored
by subunit module (PDB 5Z62). Core
mtDNA-encoded subunits (COX1  light
pink, COX2  magenta, COX3  blue)
are rendered as surface representation
whereas nuclear DNA-encoded subunits
are presented as ribbons.
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blood were cultured under the same conditions, except that the
medium was RPMI 1640 and the amount of FCS was 20% (v/v).
Gene editing was performed in HEK293T (originally purchased from
ATCC) and the NDUFV3KONDUFV3FLAG cell line published previ-
ously (32). Constructs for CRISPR-Cas9 genome editing were de-
signed using the CHOPCHOP software (33) and oligonucleotides
encoding gRNA sequences cloned into the pSpCas9(BB)-2A-GFP
(PX458) plasmid (a gift from F. Zhang; Addgene, plasmid 48138;
(34)) as previously described (32). The gRNA sequences used were
5-ATGTCAGTCAAACTTACCAA for HIGD1A and 5-ACTTACCT-
ATGGGTACCACC for HIGD2A. Constructs were transfected using Li-
pofectamine LTX (Thermo Fisher Scientific) according to manufacturer’s
instructions. Single GFP positive cells were sorted into 96 well plates
and clonal populations expanded for screening by SDS-PAGE and
immunoblotting as described below. To verify the CRISPR/Cas9 in-
duced insertions and deletions (indels) genomic DNA was isolated
from candidate clones using the Quick-DNA kit (Zymo Research,
Irvine, CA) according to manufacturer’s specifications. Oligonu-
cleotides provided by the CHOPCHOP software (33) were used
for amplification of target regions and cloning into pGEM4Z (35)
for M13 primed Sanger sequencing of individual alleles as we
have done previously (32). HIGD1AKO contained the following
mutations c.[97  2G_97  6Gdel];[97  2G_97  14Gdel];[97_97 
3Tdel] predicted to impact splicing. HIGD2AKO contained c.[145del];
[131_150del];[133_149del];[138_158del];[143_153  49Gdel] predicted
to alter the frame and introduce premature stop codons. NDUFV3KO





dicted to alter the reading frame and introduce premature stop
codons. For hypoxia treatment, cells were cultured inside a hypoxia
incubator chamber (STEMCELL Technologies, Vancouver, BC,
Canada) pre-purged with 1% O2, 5% CO2, 94% N2 for 10 min at 25
liters/min. The sealed chamber was incubated at 37 °C for 3 or 24 h
as indicated. For pulse-SILAC analysis of mitochondrial translation,
cells were incubated in DMEM as above with the overnight addition
of 50 g ml1 chloramphenicol (CAP; Sigma-Aldrich) prior to the
start of the experiment. Media was replaced with neat DMEM for
SILAC (Thermo Fisher Scientific) for 15 min following which the
media was supplemented with 10% dialyzed FCS (Thermo Fisher
Scientific), Sodium Pyruvate (Thermo Fisher Scientific), Glutamax
(Thermo Fisher Scientific), penicillin/streptomycin (Thermo Fisher
Scientific), 3.5 g/L glucose and 0.1 mg/ml cycloheximide (Sigma-
Aldrich). Following an incubation for 30 min at 37 °C under an
atmosphere of 5% CO2, media was further supplemented 1.2 g/ml
L-proline, 285 mg/ml -13C6
15N2-L-lysine-HCl and 85 mg/L-
13C6
15N2-L-arginine-HCl (Silantes, Munich, Germany). Time points
were collected at 0, 1, 2, and 4 h post addition of SILAC amino
acids.
Patient Sequencing and Enzymology Assays—The AARS2 patient
was a boy with intrauterine growth retardation who had failure to
thrive, hypotonia and developmental delay noted in the first months of
life. He had metabolic acidosis with plasma lactate levels up to 12
mmol/L (normal range 2.5 mmol/L) and developed cortical blind-
ness and temperature instability by 6 months of age with cerebral
atrophy. From about 8 months of age he suffered a rapidly progres-
sive neurodegenerative course with marked spasticity, decorticate
posturing and was in a vegetative state prior to his death at 16 months
of age. DNA was extracted from skin fibroblasts and whole exome
sequencing was performed as published (per subject 1 in reference
(36)). Our filtering strategy identified 20 rare, heterozygous, high qual-
ity, moderate-high impact variants in this patient. Most pediatric
mitochondrial disorders are autosomal recessive in origin, AARS2
was the only gene in which two such variants were identified. Electron
transport chain enzyme activities in skeletal muscle biopsies (post-
660g supernatants) and mitochondrial preparations from Epstein-Barr
Virus (EBV) transformed lymphocytes (lymphoblasts) were deter-
mined spectrophotometrically as previously described (37). Enzymes
assayed were complex I (NADH-coenzyme Q1 oxidoreductase), com-
plex II (succinate-coenzyme Q1 oxidoreductase), complex III (decyl-
benzylquinol-cytochrome c oxidoreductase), complex IV (cytochrome
c oxidase) plus the mitochondrial marker enzyme citrate synthase.
Retroviral Transduction—To rescue HIGD2A expression in
HIGD2AKO a construct encoding HIGD2A with a C-terminal FLAG tag
and compatible overhangs for Gibson assembly was commercially
synthesized (IDT technologies, Singapore). The construct was com-
bined with pBABE-puro plasmid (Addgene, 1764) cut with BamHI-HF
and HindIII-HF restriction enzymes (NEB, Notting Hill, VIC, Australia)
and Gibson assembled using the NEBuilder HiFi DNA Assembly Sys-
tem (NEB) as per manufacturer’s directions to yield pBabe-puro-
HIGD2AFLAG. The construct was used to generate viral particles in
HEK293T cells as previously described (32). Briefly, pBabe-puro-
HIGD2AFLAG was co-transfected alongside pUMVC3 and pCMV-
VSV-G (Addgene, 8449 and 8454) using Lipofectamine LTX (Thermo
Fischer Scientific) according to manufacturer’s instructions. Viral su-
pernatant was collected at 48 h post-transfection, filtered with 0.45
m PVDF membrane (Merck, Bayswater, VIC, Australia) and used to
infect HIGD2AKO cells in the presence of 8 g ml1 polybrene. Cells
were selected in puromycin at 2 g/ml for 10 days. Transduction was
verified by SDS-PAGE and immunoblotting.
SDS-PAGE, BN-PAGE and Western Blotting—SDS-PAGE was
performed using samples solubilized in LDS sample buffer (Thermo
Fisher Scientific) with presence of 50 mM DTT and separated on
Invitrogen Bolt Bis-Tris protein gels (10% or 4–12%) using the MES
running buffer according to manufacturer’s instructions (Thermo Fis-
cher Scientific). For assessing the effect of hypoxia treatment, cells
were solubilized in RIPA buffer (25 mM Tris-HCl pH7.4, 150 mM NaCl,
0.1% (w/v) SDS, 1% (v/v) Triton X-100) supplemented with 1 mM
PMSF and protease inhibitor mixture (cOmplete™, Merck) on ice.
BN-PAGE was performed using mitochondrial protein solubilized in
1% digitonin (w/v) based solubilization buffer as described previously
(38, 39). Mitochondria were isolated as previously described (40) with
protein concentration determined using the Pierce Protein Assay Kit
(Thermo Fisher Scientific). Detergent solubilized complexes were sep-
arated on Invitrogen NativePAGE Bis-Tris gels (3–12%) as per man-
ufacturer’s instructions. Western blotting of SDS-PAGE gels was
undertaken using the Invitrogen iBlot2 Dry Blotting System using
PVDF based stacks. The Invitrogen Mini Blot Module transfer system
was used to transfer BN-PAGE gels onto PVDF (Merck) as per man-
ufactures recommendations. Immunoblots were developed using
horseradish peroxidase coupled mouse and rabbit secondary anti-
bodies (Cell Signaling Technology, Danvers, MA) and ECL chemilu-
minescent substrates (Bio-Rad) and visualized on a ChemiDoc XRS
gel documentation system (Bio-Rad, Gladesville, NSW, Australia).
Commercial antibodies were obtained for COX1 (Abcam, Melbourne,
VIC, Australia; ab14705), COX2 (Abcam, ab110258), COX4 (Abcam,
ab110261), COX6A1 (Proteintech, Rosemont, IL, 11460-1-AP), FLAG
(Sigma-Aldrich, F1804), GAPDH (Proteintech, HRP-60004), HIF-1
(Santa Cruz, Dallas, TX, SC-53546), HIGD1A (Proteintech, 21749-1-
AP), HIGD2A (Proteintech, 21415-1-AP), SDHA (Abcam, Ab14715),
UQCRC1 (Abcam, AB110252), -actin (Proteintech, HRP-60008) and
used at the recommended dilutions. In-house polyclonal rabbit anti-
bodies for NDUFA9 were previously described (39). In-gel activity
assays were performed as described previously (41).
Oxygen Consumption Measurements—Mitochondrial oxygen con-
sumption rates were measured in live cells using a Seahorse Biosci-
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ence XFe-96 Analyzer (Agilent Mulgrave, VIC, Australia). Briefly,
25,000 cells were plated per well in culture plates treated with 50
g/ml poly-D-lysine (Sigma-Aldrich). For each assay cycle, there were
4 measurements of 2 min followed by mixing, 2 min wait, and 5 min
measure. The following inhibitor concentrations were used: 1 M
oligomycin, 1 M carbonyl cyanide 4-(trifluoromethoxy)phenylhydra-
zone (FCCP), 0.5 M rotenone and 0.5 M antimycin A. Data were
normalized using the Pierce Protein Assay Kit (Thermo Fisher Scien-
tific) and analyzed using Wave (version 2.6.0, Agilent) and Prism
(version 8.0.2, GraphPad) software packages. For substrate driven
oxygen consumption, cells were permeabilized in 0.025% (w/v) dig-
itonin as described (42). For each assay cycle, there were 4 meas-
urements of 2 min mix, 2 min wait and 5 min measure. The following
inhibitor concentrations and combinations were used. Port A: TMPD/
ascorbate 0.5 mM/2 mM, 1 M FCCP, ADP 1 mM; Port B: 1 M
oligomycin; Port C: Potassium azide 20 mM. Data were normalized
and analyzed as above.
Acquisition and Analysis of Steady State Mass Spectrometry Data
from Patient Lymphoblasts—Primary lymphoblasts (two subcultures
from the same individual) and controls (from three separate individu-
als) were pre-normalized based on protein concentration using the
Pierce Protein Assay Kit (Thermo Fisher Scientific). Pellets were sol-
ubilized in 1% (w/v) SDC, 100 mM Tris pH 8.1, 40 mM chloroacetamide
(Sigma-Aldrich) and 10 mM tris(2-carboxyethyl)phosphine hydrochlo-
ride (TCEP; BondBreaker, Thermo Fisher Scientific) for 5 min at 99°C
with 1500 rpm shaking followed by 15 min sonication in a waterbath
sonicator. Protein digestion was performed with trypsin (Thermo
Fisher Scientific) at a 1:50 trypsin:protein ratio at 37°C overnight. The
supernatant was transferred to stagetips containing 3  14G plugs of
3M™ Empore™ SDB-RPS substrate (Sigma-Aldrich) as described
previously (32, 43). Ethyl acetate (99% v/v) and 1% (v/v) TFA was
added to the tip before centrifugation at 3000 g at room temperature.
Stagetips were washed first with the same ethyl acetate containing
solution and then subjected to an additional wash with 0.2% (v/v)
TFA. Peptides were eluted in 80% (v/v) acetonitrile (ACN) and 1%
(w/v) NH4OH, and then acidified to a final concentration of 1% TFA
prior to drying in a CentriVap Benchtop Vacuum Concentrator (Lab-
conco, Kansas City, MO) and reconstituted in 0.1% TFA and 2% ACN
for analysis by Liquid chromatography (LC) - MS/MS on an Orbitrap
QExactive Plus (Thermo Fisher Scientific) coupled with an Ultimate
3000 HPLC (Thermo Fisher Scientific) and NanoESI interface. Pep-
tides were injected onto the trap column (Acclaim C18 PepMap nano
Trap x 2 cm, 100 m I.D, 5 m particle size and 300 Å pore size;
Thermo Fisher Scientific) at a flow rate of 15 l/min before switching
the trap in-line with the analytical column (Acclaim RSLC C18 PepMap
Acclaim RSLC nanocolumn 75 m  50 cm, PepMap100 C18, 3 m
particle size 100 Å pore size; Thermo Fisher Scientific). The peptides
were eluted using a 250 nL/min non-linear ACN gradient of buffer A
(0.1% FA, 2% ACN) buffer B (0.1% FA, 80% ACN) increasing from
2.5% to 35.4% followed by a ramp to 99% over 278 min. Data were
acquired in positive mode using data dependent acquisition 375–
1800 m/z as a scan range, HCD for MS/MS of the top 12 intense ions
with charges  2. MS1 scans were acquired at 70,000 resolution (at
200 m/z), MS max. injection time of 54 ms, AGC target 3e6, NCE at
27%, isolation window of 1.8 Da, MS/MS resolution of 17,500,
MS/MS AGC target of 2e5. Raw files were processed using the
MaxQuant platform (version 1.6.0.16) (44) and searched against Uni-
Prot human database (93,588 entries, Aug 2017) and a list of common
contaminants using default settings for a label free quantification
(LFQ) experiment with “LFQ,” “re-quant” and “Match between runs”
enabled. For this search Trypsin/P cleavage specificity (cleaves after
lysine or arginine, even when proline is present) was used with a
maximum of 2 missed cleavages. Oxidation of methionine and N-ter-
minal acetylation were specified as variable modifications. Carbam-
idomethylation of cysteine was set as a fixed modification. A search
tolerance of 4.5 ppm was used for MS1 and 20 ppm for MS2
matching. False discovery rates (FDR) were determined through the
target-decoy approach set to 1% for both peptides and proteins.
The proteinGroups.txt output from the search was processed in
Perseus (version 1.6.2.2) (45). Briefly, Log2-transformed LFQ Inten-
sities were grouped into patient or control groups consisting of
three controls and two replicates of the patient lymphoblasts. Iden-
tifications filtered to include only those that were quantified in at
least two samples from each group. Annotations for proteins pres-
ent in the Mitocarta2.0 dataset (46) were added through matching
by gene name. A two-sided t-test with significance determined by
permutation-based FDR statistics (FDR 5%, S0  0.1) was per-
formed with results expressed as a volcano plot.
Acquisition and Analysis of Steady State Mass Spectrometry Data
from HEK293T Cells—Crude mitochondrial protein from HEK293T,
HIGD2AKO, and HIGD1AKO cells and whole cell material from hypoxia
treated HEK293T cells (derived from two independent subcultures of
each) were pre-normalized using the Pierce Protein Assay Kit (Thermo
Fisher Scientific). Protein pellets were solubilized and digested into
tryptic peptides for mass spectrometry using the iST-NHS kit
(PreOmics GmbH, Planegg, Germany) as per manufacturer instruc-
tions. Peptides were labeled with 6plex Tandem Mass Tags (TMT)
(Thermo Fisher Scientific) in 8:1 label:protein ratio as per manufac-
turer instructions. Pooled samples were fractionated using the Pierce
High pH Reversed-Phase Peptide Fractionation Kit (Thermo Fisher
Scientific) as per manufacturer’s instructions. Individual fractions
were dried using a CentriVap Benchtop Vacuum Concentrator (Lab-
conco) and reconstituted in 2% (v/v) acetonitrile (ACN) and 0.1% (v/v)
trifluoroacetic acid (TFA). Liquid chromatography (LC) coupled
MS/MS was carried out on an Orbitrap Lumos mass spectrometer
(Thermo Fisher Scientific) with a nanoESI interface in conjunction with
an Ultimate 3000 RSLC nanoHPLC (Dionex Ultimate 3000). The LC
system was equipped with an Acclaim Pepmap nano-trap column
(Dionex-C18, 100 Å, 75 m  2 cm) and an Acclaim Pepmap RSLC
analytical column (Dionex-C18, 100 Å, 75 m  50 cm). The tryptic
peptides were injected to the trap column at an isocratic flow of 5
l/min of 2% (v/v) CH3CN containing 0.1% (v/v) formic acid for 5 min
applied before the trap column was switched in-line with the analyt-
ical column. The eluents were 5% DMSO in 0.1% v/v formic acid
(solvent A) and 5% DMSO in 100% v/v CH3CN and 0.1% v/v formic
acid (solvent B). The flow gradient was (1) 0–6min at 3% B, (2) 6–95
min, 3–22% B (3) 95–105 min 22–40% B (4) 105–110 min, 40–80% B
(5) 110–115 min, 80–80% B (6) 115–117 min, 80–3% and equili-
brated at 3% B for 10 min before the next sample injection. The
Synchronous Precursor Selection (SPS)–MS3 based TMT method
was used. In brief, a full MS1 spectra was acquired in positive mode
at 120,000 resolution scanning from 380–1500 m/z. AGC target was
at 4e5 and maximum injection time of 50ms. Precursors for MS2/MS3
analysis were selected based on a Top 3 s method. MS2 analysis
consists of collision induced dissociation (CID) with isolation window
of 0.7 in the quadrupole. CID was carried out with normalized collision
energy of 35 and activation time of 10 ms with detection in the ion
trap. Following acquisition of each MS2 spectrum, multiple MS2
fragment ions were captured in the MS3 precursor population using
isolation waveforms frequency notches. The MS3 precursors were
fragmented by high energy collision-induced dissociation (HCD) and
analyzed using the Orbitrap with scan range of 100–500 m/z, 60,000
resolution, normalized collision energy of 60%, AGC target of 1e5 and
maximum injection time of 120ms. Raw files were processed using
the MaxQuant platform (version 1.6.3.3) (44) and searched against
UniProt human database (42,434 entries, June 2019) using default
settings for a TMT 6plex experiment with the following modifications:
deamination (NQ), oxidation of methionine and N-terminal acetylation
HIGD2A is Critical in Assembly of Human Complex IV
1148 Mol Cell Proteomics (2020) 19(7) 1145–1160
were specified as variable modifications. Trypsin/P cleavage speci-
ficity (cleaves after lysine or arginine, even when proline is present)
was used with a maximum of 2 missed cleavages. Carbamidomethy-
lation of cysteine was set as a fixed modification. A search tolerance
of 4.5 ppm was used for MS1 and 20 ppm for MS2 matching. False
discovery rates (FDR) were determined through the target-decoy
approach set to 1% for both peptides and proteins. The protein-
Groups.txt output from the search was processed in Perseus (version
1.6.2.2) (45). Briefly, Log2-transformed TMT reporter intensity cor-
rected values were grouped into wild-type, HIGD2A and HIGD1A
groups consisting of two replicates each. Identifications filtered to
include 100% valid values across all samples. Annotations for pro-
teins present in the Mitocarta2.0 dataset (46) were added through
matching by gene name and rows filtered to include only mitochon-
drial entries. A two-sided t test with significance determined by per-
mutation-based FDR statistics (FDR 5%, S0  1) was performed with
results expressed as a volcano plot. Ratios for individual subunits
relative to controls were mapped onto the Cryo-EM PDB maps cited
in the figure legends using a custom python script described previ-
ously (32).
Acquisition and Analysis of Pulse-SILAC Mass Spectrometry
Data—Mitochondrial protein pellets (from three independent subcul-
tures) were solubilized in 1% (w/v) SDC, 100 mM Tris pH 8.1, 40 mM
chloroacetamide (Sigma) and 10 mM tris(2-carboxyethyl)phosphine
hydrochloride (TCEP; BondBreaker, Thermo Fisher Scientific) for 5
min at 99°C with 1500 rpm shaking followed by 15 min sonication in
a waterbath sonicator. Protein digestion was performed with trypsin
(Thermo Fisher Scientific) at a 1:50 trypsin/protein ratio at 37°C over-
night. The supernatant was transferred to stagetips containing 3 
14G plugs of 3M™ Empore™ SDB-RPS substrate (Sigma-Aldrich) as
described previously (32, 43) and above. Analysis of reconstituted
peptides was performed by LC MS/MS on a QExactive Plus Orbitrap
mass spectrometer (Thermo Fisher Scientific) in conjunction with an
Ultimate 3000 RSLC nanoHPLC (Dionex Ultimate 3000). The LC sys-
tem was as described above (Acquisition and Analysis of Steady
State Mass Spectrometry Data from HEK293T Cells). For this exper-
iment the mass spectrometer was operated in the data-dependent
mode with a targeted inclusion list containing predicted peptides from
the 13 mitochondrial DNA-encoded proteins. The inclusion list con-
sists of mass/charge (m/z) and charge (z) of tryptic peptides (endog-
enous and SILAC labeled) predicted from in-silico digest of target
proteins using the Skyline software (47). In addition, the inclusion list
also contained peptides that have been previously observed in public
data depositories through the PeptideAtlas site (48) and the present
study. Full MS1 spectra were acquired in positive mode, 140,000
resolution, AGC target of 3e6 and maximum IT time of 50 ms. A loop
count of 10 on the most intense targeted peptide were isolated for
MS/MS. The isolation window was set at 1.2 m/z and precursors
fragmented using stepped normalized collision energy of 28, 30 and
32. Resolution was at 35,000 resolution, AGC target at 2e5 and
maximum IT time of 150 ms. Dynamic exclusion was set to be 30 s.
Raw files were processed using the MaxQuant platform (version
1.6.3.3) (44) and searched against UniProt human database (20,336
entries, May 2018) using default settings for a SILAC experiment. For
this search Trypsin/P cleavage specificity (cleaves after lysine or
arginine, even when proline is present) was used with a maximum of
2 missed cleavages. Oxidation of methionine and N-terminal acety-
lation were specified as variable modifications. Carbamidomethyla-
tion of cysteine was set as a fixed modification. A search tolerance of
4.5 ppm was used for MS1 and 20 ppm for MS2 matching. False
discovery rates (FDR) were determined through the target-decoy
approach set to 1% for both peptides and proteins. The “Requant”
option was set to “on.” The proteinGroups.txt output from the search
was processed in Perseus (version 1.6.2.2) (45). Briefly, heavy inten-
sity values for the detected mtDNA encoded proteins were Log2
transformed and values were normalized to the maximum value de-
tected in the control 4 h condition. The means from three experiments
were plotted over time using Prism (version 8.1.2, GraphPad) along
with the standard deviation from the mean of replicates.
Acquisition and Analysis of Affinity Enrichment Mass Spectrometry
Data—Affinity enrichment experiments were performed on comple-
mented HIGD2AFLAG cells. In brief, 1 mg of whole-cell protein pellets
from HEK293T and HIGD2AFLAG (derived from three subcultures of
each) were harvested in triplicate and solubilized in 20 mM Tris-Cl pH
7.4, 50 mM NaCl, 10% (v/v) glycerol, 0.1 mM EDTA, 1% (w/v) digitonin
and 125 units of benzonase (Merck). Pierce™ Spin Columns (Thermo
Fisher Scientific) were loaded with 40 l anti-FLAG M2 affinity gel
(Sigma-Aldrich) and equilibrated with wash buffer (20 mM Tris-Cl pH
7.4, 60 mM NaCl, 10% v/v glycerol, 0.5 mM EDTA, 0.1% w/v digitonin).
Clarified (20,000  g, 5 mins at 4°C) lysate was added to spin
columns containing FLAG beads and incubated at 4 °C for 2 h in
rotating mixer. Columns were attached to a vacuum manifold and
washed 30 times with 500 l of wash buffer. For elution, 100 l of
wash buffer containing 100 g/ml of FLAG peptide; Sigma-Aldrich)
for 30 min at 4 °C prior to low speed centrifuge and collection into a
microcentrifuge tube. Another 100 l of wash buffer (not containing
FLAG peptide) was added and both elutions were pooled into the
same tube. Eluted proteins were precipitated with 5 volume of
ice-cold acetone overnight at 20 °C. On the next day, samples were
centrifuges at max speed for 10 min at room temperature and the
precipitated protein pellet was solubilized with 8 M urea in 50 mM
ammonium bicarbonate (ABC) followed by sonication for 15 min in a
sonicator water bath. To reduce and alkylate proteins tris(2-carboxy-
ethyl)phosphine hydrochloride (TCEP; Bondbreaker, Thermo Fisher
Scientific) and chloroacetamide (Sigma-Aldrich) were added to a final
concentration of 10 mM and 50 mM respectively and incubated at
37 °C for 30 min while shaking. Samples were diluted to 2 M urea
using 50 mM ABC prior to digestion with 1 g of trypsin (Thermo
Fisher Scientific) at 37 °C overnight. Peptides were acidified to 1%
TFA and desalted using stagetips (43) containing 2  14G plugs of
3M™ Empore™ SDB-XC Extraction Disks (Sigma-Aldrich) which
were pre-activated with 100% acetonitrile (ACN) and equilibrated with
0.1% TFA, 2% ACN prior to sample loading. Column was washed
with 0.1% TFA, 2% ACN and samples were eluted with 80% ACN,
0.1% TFA. All centrifugation steps were performed at 1,800 g. Elu-
tions were dried using CentriVap concentrator (Labconco) and sam-
ples were reconstituted in 0.1% TFA, 2% ACN. LC-MS/MS was
carried out on a LTQ Orbitrap Elite (Thermo Scientific) in conjunction
with an Ultimate 3000 RSLC nanoHPLC (Dionex Ultimate 3000). The
LC system was as described above (Acquisition and Analysis of
Steady State Mass Spectrometry Data from HEK293T Cells). The LTQ
Orbitrap Elite was operated in the data-dependent mode with na-
noESI spray voltage of 1.8kV, capillary temperature of 250 °C and
S-lens RF value of 55%. All spectra were acquired in positive mode
with full scan MS spectra from m/z 300–1650 in the FT mode at
120,000 resolution. Automated gain control was set to a target
value of 1.0e6. Lock mass of 445.120025 was used. The top 20
most intense precursors were subjected to rapid collision induced
dissociation (rCID) with normalized collision energy of 30 and acti-
vation q of 0.25. Dynamic exclusion with of 30 s was applied for
repeated precursors. Raw files were analyzed using MaxQuant
platform (44) (version 1.6.5.0) and searched against UniProt human
database (42,410 entries, January 2019) using default LFQ search
parameters with the following modifications: LFQ min. ratio count
and label min. ratio count  1. For this search Trypsin/P cleavage
specificity (cleaves after lysine or arginine, even when proline is
present) was used with a maximum of 2 missed cleavages. Oxida-
tion of methionine and N-terminal acetylation were specified as
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variable modifications. Carbamidomethylation of cysteine was set
as a fixed modification. A search tolerance of 4.5 ppm was used for
MS1 and 20 ppm for MS2 matching. False discovery rates (FDR)
were determined through the target-decoy approach set to 1% for
both peptides and proteins. Data analysis was performed using
Perseus framework (45) (version 1.6.2.2). Briefly, LFQ intensities
imported from the proteinGroups.txt output were Log2 transformed.
Only proteins quantified across all three IP samples (with no re-
strictions on control identifications) were included and the missing
control values imputed at the limit of detection based on normal
distribution. Experimental groups were assigned to each set of
triplicates and a two-sided t test performed with significance de-
termined by permutation-based FDR statistics (FDR 5%, S0  1) to
exclude all identifications enriched in control samples.
Experimental Design and Statistical Rationale—For label-free and
TMT-labeled analyses of whole cells or mitochondria, the statistical
approaches used to analyze the data were consistent with pub-
lished analyses from ours (32, 49) and other labs employing similar
instrumentation and methods. The log2 ratio values were normally
distributed. The fold change threshold we used for significance was
determined through a modified two-sided t test based on permu-
tation-based FDR statistics between the two groups, with an FDR
of 5% and the s0 value determined by the main distribution of
quantified proteins. AEMS experiments were performed in triplicate
using LFQ and compared with control cells as we have done
previously (32, 49). Imputation was applied only to controls and
random values drawn from a distribution equivalent to the limit of
detection in each experiment. The log2 intensity values were nor-
mally distributed. Significantly enriched proteins were determined
through a modified two-sided t test based on permutation-based
FDR statistics (45) between the two groups, with an FDR of 5% and
the s0 value set to exclude enriched proteins specific to the control
group. For the pulse-chase SILAC experiment rows for mtDNA
encoded proteins were isolated and log2 heavy proteinGroup inten-
sities scaled to the maximum intensity observed for the protein-
Group in control cells.
RESULTS
HIGD2A is Up-regulated in Patient Lymphoblasts with an
Isolated Complex IV Deficiency—We identified a patient pre-
senting with intrauterine growth retardation, developmental
delay, cortical blindness, possible deafness, lactic acidosis,
and cardiomyopathy. The patient died at 16 months of age.
Enzymology revealed an apparently isolated complex IV
defect in muscle and lymphoblasts (Table I). Whole exome
sequencing revealed two novel compound heterozygous
missense mutations (c.1874GA, p.Arg625His; c.665CT
p.Thr222Ile) in AARS2, which encodes for mitochondrial ala-
nine-tRNA synthetase (MIM 612035). Both mutations are clas-
sified as class 4 or ‘likely pathogenic’ (PM2, PP3, PS3) using
the ACMG standards and guidelines for the interpretation of
sequence variants (50). It is not uncommon to find an appar-
ently isolated ETC enzyme defect in genetic defects that
would be expected to affect multiple ETC enzymes (51). Given
that AARS2 lymphoblasts harbor an isolated complex IV de-
fect, we utilized them to search for novel proteins involved in
assembly of complex IV. We performed quantitative mass
spectrometry on the patient lymphoblasts and on control
lymphoblasts from three unaffected individuals, as we have
done previously for patient fibroblasts (36). We quantified the
levels of 3877 cellular proteins detected in AARS2 lympho-
blasts and in at least two out of three control cell lines (sup-
plemental Table S1), revealing significant reduction in the
levels of complex IV subunits but not subunits of complexes I,
III, or V (Fig. 2) consistent with enzymology data. HIGD2A was
the most up-regulated mitochondrial protein in AARS2 lym-
phoblasts relative to control cell lines.
Loss of HIGD2A Leads to Defective Assembly of Complex
IV—To clarify the function of HIGD2A we used CRISPR/Cas9
to generate human embryonic kidney (HEK293T) cell lines
lacking its expression (supplemental Fig. S1). We also gener-
ated cell lines lacking the HIGD2A ortholog HIGD1A. Loss of
HIGD1A (HIGD1AKO) led to no changes in the steady state
level of complex IV subunits (supplemental Fig. S1A), whereas
loss of HIGD2A (HIGD2AKO) led to a strong reduction in the
levels of COX2 (supplemental Fig. S1B), the core subunit of
the COX2 module, and the total loss of COX6A, a nuclear
encoded subunit present within the COX3 module. To assess
the assembly of complex IV and supercomplexes we per-
formed Blue Native (BN)-PAGE. When using the weak non-
FIG. 2. HIGD2A is up-regulated in lymphoblasts with a specific
defect in the translation of mtDNA-encoded complex IV subunits.
Volcano plot comparing mitochondrial protein abundances for pro-
teins quantified in AARS2 lymphoblasts relative to control lympho-
blasts. Subunits of complexes I, III and IV are colored as indicated.
The curved line indicates significantly altered protein abundance de-
termined through a false discovery rate-based approach (5% FDR,
s0  0.1). n  2 subcultures for the patient cells and n  3 independ-
ent controls.
TABLE I
Primary human lymphoblasts with mutated AARS2 have an isolated
complex IV defect. Electron transport chain enzyme activities in skel-
etal muscle homogenate and EBV-Lymphoblast mitochondria are ex-
pressed as %CS ratio, which represents % of the normal control mean
value when expressed relative to the mitochondrial marker enzyme
Citrate Synthase. Bold characters indicate clinically significant abnor-






Patient Ref. Range(n  9) Patient
Ref. Range
(n  6)
Complex I 52 36–167 75 78–116
Complex II 129 52–156 92 47–142
Complex III n.t. 62–185 155 64–132
Complex IV 12 36–192 38 76–126
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ionic detergent digitonin, BN-PAGE can resolve stalled com-
plex IV assembly intermediates, holo complex IV and multiple
high-order supercomplex structures (10, 17, 20, 52, 53). As
can be seen in Fig. 3A, HIGD2AKO mitochondria contain re-
duced levels of the primary supercomplex assembly consist-
ing of CI/III2/IV (compare lanes 1,2, and 2,5). Additionally,
HIGD2AKO mitochondria accumulate both the S2 intermediate
containing COX1 and COX4 (Fig. 3A compare lanes 7,8 and
10,11) and S3 intermediate containing COX2, consistent with
defective assembly of complex IV (9, 16, 53). Strikingly, no
signal was observed for COX3 module subunit COX6A1, ei-
ther in accumulated intermediates or mature complex IV as-
semblies (Fig. 3A compare lanes 16,17). In contrast to
HIGD2AKO, mitochondria lacking HIGD1A contained normal
levels and distribution of supercomplex assemblies and ac-
cumulated complex IV intermediates were not detected
(Fig. 3A).
HIGD2A is Required for the Stability of COX3 Module of
Complex IV—To confirm the steady levels of complex IV
subunits in HIGD2AKO mitochondria we performed quan-
titative mass-spectrometry. Mitochondrial proteins from
HIGD2AKO, HIGD1AKO and control cells were digested, and
tryptic peptides labeled with tandem mass tags (TMT) prior to
pooled analysis and synchronous precursor selection (SPS)–
MS3 based acquisition. We quantified the levels of 892 pro-
teins present within the Mitocarta2.0 (46) inventory of mito-
chondrial proteins across all samples (supplemental Table
S2). As can be seen in Fig. 3B (left panel) HIGD2AKO mito-
chondria contained a significant reduction in the levels of
complex IV subunits COX3 (MT-CO3), COX6A1, COX6B1,
COX7A2, as well as COX2 (MT-CO2) and NDUFA4, a subunit
originally ascribed to complex I but now known to be present
within complex IV (52). Other complex IV subunits were de-
tected but found not to be significantly altered relative to
control cells. HIGD2AKO mitochondria also contained signifi-
cantly increased levels of complex IV assembly factors COA4,
COA6, COA7, CMC2, and COX11 (9, 16). In contrast our,
analysis of HIGD1AKO mitochondria revealed a significant re-
duction in the levels of a different cohort of complex IV sub-
units; COX1 (MT-CO1), COX4, and COX5A, as well as assem-
bly factors SCO2 and COX18 (Fig. 3B, right panel). COA7 was
also found in HIGD1AKO mitochondria at increased abun-
dance relative to controls. Notably, the fold change in abun-
dance of complex IV subunits was less in HIGD1AKO (	1–1.5
fold change) than for HIGD2AKO (	2–3 fold change) consist-
ent with the strong defect in assembly we observed for the
latter (Fig. 3A).
We used topographical heatmaps (32) to interpret our
mass-spectrometry data in the context of the intact 14-
subunit human holo complex IV (54) and CI/III2/IV respira-
tory chain supercomplex (2) structures recently determined
by single particle cryo-electron microscopy. Both structures
were determined using complexes isolated from the same
HEK293T derived human cell line used in our study. Unsu-
pervised hierarchical clustering of knockout to control pro-
tein ratios from both cell lines revealed several clusters of
FIG. 3. Loss of HIGD2A leads to de-
fects in assembly of complex IV. A,
Mitochondria isolated from the indicated
cell lines were solubilized in 1% digito-
nin, analyzed by BN-PAGE and immuno-
blotted (IB) using antibodies specific for
the indicated antibodies. CIVS2, complex
IV stage II intermediate; CIVS3, complex
IV stage 3 intermediate. B, Volcano plots
depicting relative levels of mitochondrial
proteins in HIGD2AKO and HIGD1AKO
cell lines compared with HEK293T cells.
Black dots and the curved line represent
significantly altered protein abundance
determined through a false discovery
rate-based approach (5% FDR, s0  1).
n  2 independent subcultures.
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co-dependent subunits from complexes I, III, and IV (Fig.
4A). The most strongly clustered cohort of proteins in
HIGD2AKO belonged to the COX3 module (Figs. 4A, 4B). We
found NDUFA4 to be strongly correlated with these pro-
teins, suggestive of it being a subunit of the COX3 module.
Mapping of our data to the supercomplex (Fig. 4C) revealed
the affected complex I and III subunits to be predominantly
located at contact sites with complex IV. In contrast, loss of
HIGD1A led to the comparatively weak clustering of COX1
and COX2 module subunits (Figs. 4A, 4D). Taken together,
our data suggest that loss of HIGD2A strongly affects the
COX3 module of complex IV, leads to accumulation of a
crippled complex IV and its defective association with com-
plexes I and III in the respiratory chain supercomplex.
Loss of HIGD2A Leads to Impaired Complex IV Activity—
HIGD2AKO cells die in media where glucose has been re-
placed with galactose (data not shown), indicative of severely
impaired mitochondrial respiration (32, 53). To investigate the
impact of HIGD2A and HIGD1A on mitochondrial energy gen-
eration we measured the oxygen consumption rates in our
HIGD2AKO and HIGD1AKO cell lines. Cells lacking HIGD2A
were significantly impaired in basal and maximal respiration
(Fig. 5A). In contrast, HIGD1AKO had impaired basal respira-
tion but similar maximal respiration compared with control
cells leading to an increase in spare respiratory capacity. To
investigate the source of the respiration defects we performed
an in-gel complex IV activity assay (41). As can be seen in Fig.
5B, the remnant complex IV found within HIGD2AKO mito-
chondria showed only background levels of activity. Although
activity was detected in the HIGD2AKO CI/III2/IV supercom-
plex it was reduced relative to control cells. In contrast, com-
plex IV activity in holo complex IV as well as the supercomplex
was unaltered in HIGD1AKO mitochondria. Finally, to confirm
the impact of HIGD2A loss on complex IV activity in vivo we
measured complex IV-linked respiration (42). Briefly, the
electron donor N,N,N,N-Tetramethyl-p-phenylenediamine
(TMPD) is provided in the presence of ascorbate to semi-
permeabilized cells where it donates electrons to cytochrome
c thereby bypassing complex III (Fig. 5C). When TMPD was
added to control HEK293T cells in the presence of ADP and
uncoupler FCCP, we observed maximal mitochondrial res-
FIG. 4. Loss of HIGD2A affects the
COX3 module of complex IV. A, Two-
dimensional heatmap showing hierarchi-
cally clustered protein ratios for subunits
of complex I, III and IV. Modules of com-
plex IV are indicated with the colored
squares. B, Topographical heatmap
showing protein ratios for subunits of
complex IV in HIGD2AKO cells (PDB 5Z62)
C, Topographical heatmap showing pro-
tein ratios for subunits of the human su-
percomplex in HIGD2AKO cells (PDB
5XTH). The insets show the orientation of
the complex with complexes I and III col-
ored in orange and green respectively. D,
Topographical heatmap showing protein
ratios for subunits of complex IV in
HIGD1AKO cells (PDB 5Z62).
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piration that could be partially dissipated with oligomycin.
Inhibition of complex IV activity with azide reveals complex
IV dependent oxygen consumption. In contrast to control
cells, HIGD2AKO cells had significantly impaired complex IV
dependent respiration (Fig. 5C). Taken together, we con-
clude that loss of HIGD2A leads to a specific defect in
complex IV enzymatic activity leading to impaired mito-
chondrial respiration.
HIGD2A Acts on Complex IV Assembly Independent of
Oxygen Levels—Mammalian HIGD1A and HIGD2A were orig-
inally discovered as proteins induced following hypoxic stress
(29, 30), an insult that is known to ultimately lead to turnover
of OXPHOS subunits, a reduction in oxidative capacity and an
increase in glycolysis. As a way of compensation to these
changes in conditions, during the initial stages of hypoxia
HIGD1A has been proposed to bind complex IV and promote
its activity (31). To address whether the presence or absence
of HIGD2A impacts complex IV under hypoxia we cultured
HEK293T cells under an atmosphere of 1% oxygen for 0, 3 or
24 h. Growth under these conditions led to a robust hypoxic
response that we measured through TMT-based quantitative
mass-spectrometry (supplemental Table S3) and Western
blotting (supplemental Fig. S2). Following 24 h under hypoxic
conditions, proteins involved in glycolysis including SLC2A1,
the primary plasma membrane glucose transporter, were sig-
nificantly up-regulated (supplemental Fig. S2A). In contrast,
subunits of the OXPHOS machinery and the mitochondrial
ribosome were significantly decreased, as expected (55). Sta-
bilization of HIF1 was observed within 3 h (supplemental Fig.
S2B), as expected. Although we found HIGD1A and complex
IV subunits were indeed increased in abundance at the early
stages of hypoxia (3 h; supplemental Figs. S2B, S2C), the
steady state level of HIGD2A was unaffected (supplemental
Fig. S2B, compare lanes 1, 2). Finally, we investigated the
effects of hypoxia on assembly of complex IV and the super-
complex. Loss of neither HIGD2A nor HIGD1A altered the
effects of hypoxia on assembly of the supercomplex (supple-
mental Fig. S2B, lower panels). Moreover, following chronic
hypoxia (24 h) we observed accumulation of the S2 interme-
diate in both cell lines consistent with the complexes being
increasingly sensitive to destabilization in the absence of
HIGD2A and HIGD1A. Taken together we conclude that
HIGD2A acts on complex IV assembly independent of oxygen
levels.
FIG. 5. Biochemical characterization of mitochondrial respiration and complex IV activity in HIGD2AKO cells. A, Oxygen consumption
rates (OCR) of HIGD2AKO, HIGD1AKO and control cell lines. Data reported as mean 
 S.D. n  5. **, p  0.01; ***, p  0.001; ****, p  0.0001.
B, Mitochondrial complexes solubilized in 1% digitonin were separated by BN-PAGE and the activity of complex IV determined through an
in-gel assay. The gel was subsequently stained with coomassie (right panel). C, Flux analysis of complex IV activity in HIGD2AKO. OCR was
determined in semi-permeabilized cells with the addition of electron donor N,N,N,N-Tetramethyl-p-phenylenediamine (TMPD) and ascorbate
that donate electrons to cytochrome c bypassing complex III (see schematic). The presence of ADP and FCCP permit maximal respiration.
Complex V is inhibited by the addition of oligomycin and complex IV through azide revealing complex IV activity (top right). Data reported as
mean 
 S.D. n  2 and 3, *, p  0.05.
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HIGD2A is Required for the Biogenesis of COX3—Because
our results for HIGD1A function were broadly consistent with
previous studies, suggesting its involvement in regulating the
COX1 module following hypoxia (31), we focused our efforts
on clarifying the function of HIGD2A under normoxic condi-
tions. To identify the interaction partners of HIGD2A we
used a retroviral system to express FLAG-tagged HIGD2A
(HIGD2AFLAG) in our HIGD2AKO cell line. Ectopic expression
of HIGD2AFLAG led to rescue of supercomplex distribution
and an increase in the levels of fully assembled holo complex
IV (Fig. 6A). HIGD2AFLAG cells were then solubilized in digito-
nin and complexes bound to FLAG-affinity gel, following
which significantly enriched interactors were identified by af-
finity enrichment mass-spectrometry (AEMS). As can be seen
in Fig. 6B, HIGD2AFLAG associates with subunits of complex
IV with mtDNA encoded COX3 (MT-CO3) being the most
strongly enriched (supplemental Table S4). Interestingly, we
observed significant enrichment of complex I subunits, sub-
units of the mitochondrial ribosome (MRPL23, MRPL27 and
MRPL50), HIGD1A, complex IV assembly factors COA3
(56–59) and SCO1 (60, 61), and complex I assembly factors
NDUFAF2 (39, 62, 63) and NDUFAF4 (64) which is suggestive
of the enriched cohort of proteins representing an assembly
intermediate rather than the mature complex.
Given the enrichment of the mitochondrial ribosome and
the strong association of HIGD2AFLAG with mtDNA-encoded
COX3, we asked if mtDNA-encoded subunit translation was
affected upon loss of HIGD2A. Typically, translation and sta-
bility of mtDNA-encoded subunits is assessed using a radio-
active pulse-chase assay and analysis by SDS-PAGE and
autoradiography (65). Because COX2 and COX3 have a sim-
ilar migration on SDS-PAGE (53) we sought to develop a
mass-spectrometry based approach capable of clear differ-
entiation between these two proteins. HIGD2AKO and control
cells conditioned by overnight treatment with mtDNA transla-
tion inhibitor chloramphenicol were pulsed in media contain-
FIG. 6. HIGD2A is required for the
stability of newly translated COX3. A,
The HIGD2AKO cell line was comple-
mented with a retroviral HIGD2AFLAG
construct and mitochondria analyzed
by BN and SDS-PAGE and immunoblot-
ting with the indicated antibodies.
B, Affinity-enrichment mass spectrome-
try (AE-MS) was performed on the
HIGD2AKOHIGD2AFLAG cell line and sig-
nificant interaction partners visualized
through a volcano plot. The curved
line indicates significance determined
through an FDR-based approach
(FDR5%, S0  1). n  3. C, Pulse
SILAC analysis of newly translated
mtDNA encoded OXPHOS subunits in
HIGD2AKO cells. SILAC media was
added following overnight treatment
with chloramphenicol (CAP) and analysis
was performed at 0, 1, 2- and 4-hours
post media addition. Log2 transformed
heavy peptide-derived intensities were
plotted relative to controls. Data re-
ported as mean 
 S.D. n  3. D, As for
C but heavy media exchanged with light
media after a 3h pulse and cells cultured
for the indicated times. n  2.
HIGD2A is Critical in Assembly of Human Complex IV
1154 Mol Cell Proteomics (2020) 19(7) 1145–1160
ing SILAC (stable isotope labeling by amino acids in cell




lysine for 1, 2 and 4 h prior to analysis by targeted mass-
spectrometry (described in the methods). Using this tech-
nique, we could monitor the translation of 10 out of 13 mtDNA
encoded subunits (supplemental Table S5) including COX2
and COX3. As can be seen in Fig. 6C we observed a signifi-
cant defect in accumulation of newly translated COX3 (MT-
CO3) whereas translation of other mtDNA-encoded subunits
was comparable to control cells. This result led us to ask if the
defect in biogenesis of newly translated COX3 occurs be-
cause of rapid turnover of the subunit. To address this ques-
tion, HIGD2AKO and control cells treated as above were
pulsed with SILAC media for 3 h to accumulate newly trans-
lated COX3. At the conclusion of the pulse, the amount of
newly translated COX3 in HIGD2AKO was 	60% of that ob-
served in control cells (Fig. 6D). The accumulation of other
newly translated subunits in HIGD2AKO was like control cells,
as expected. SILAC media was exchanged with media con-
taining normal amino acids and the stability of SILAC labeled
proteins chased for 3 and 24 h. We observed time dependent
turnover of most subunits as is observed in the classic radio-
labeled translation assay (67). The turnover rate of newly
translated COX3 was similar in both HIGD2AKO and control
cells, suggesting the defect in COX3 occurs prior to the
chase. Moreover, COX3 turnover in HIGD2AKO was like the
rates observed for other mtDNA encoded proteins observed
in both cell lines. Taken together we conclude that the defect
in COX3 biogenesis observed in HIGD2AKO occurs early dur-
ing subunit translation and maturation.
HIGD2AKO Mitochondria Contain Supercomplexes Lacking
COX3—Given the apparent retention of the CI/III2/IV super-
complex in HIGD2AKO we sought an alternate approach to
assess supercomplex content. We utilized a cell line we de-
veloped previously that stably expresses the FLAG-tagged
complex I subunit NDUFV3 in the corresponding NDUFV3KO
cell line (32). NDUFV3 is suggested to be the final subunit
added to complex I during its biogenesis and we previously
used the resulting NDUFV3FLAG cell line to enrich all detect-
able subunits of complexes I, III and IV (32) leading us to
hypothesize that the cell line can be used to isolate the intact
supercomplex. To this end we used CRISPR/Cas9 to gener-
ate HIGD2A knockout mutations in the NDUFV3FLAG cell line.
HIGD2AKO and NDUFV3FLAGHIGD2AKO have comparable de-
fects in complex IV assembly and supercomplex distribution
(Fig. 7A). Next, we performed affinity enrichment and mass-
spectrometry on both the original NDUFV3FLAG and
NDUFV3FLAGHIGD2AKO cell lines. Although NDUFV3FLAG
cells co-isolated complex I, III, and IV subunits as expected
(Fig. 7B), we also detected HIGD2A, the known complex IV
assembly factor COA3 and a number of other mitochondrial
housekeeping proteins also detected in our original experi-
ment (supplemental Table S6 and (32)). We conclude that
although the NDUFV3FLAG eluate does not represent the pu-
rified supercomplex seen in the recent structures it likely
represents a late stage assembly intermediate with a full
complement of complex I, III, and IV subunits and selected
assembly factors. Finally, to assess the impact of HIGD2A
loss on the supercomplex we performed the affinity enrich-
ment experiment from NDUFV3FLAGHIGD2AKO cells using
NDUFV3FLAG as the control cell line. As can be seen in Fig.
7C, although the majority of complex I, III, and IV subunits
were equally enriched from both cell lines, significantly lower
amounts of COX3 were enriched from the pool of supercom-
plex intermediates isolated from cells lacking HIGD2A.
DISCUSSION
In this study we aimed to clarify the roles of hypoxia induc-
ible gene 1 domain family members HIGD2A and HIGD1A. To
achieve this, we utilized CRISPR/Cas9 gene editing to gener-
FIG. 7. The supercomplex in HIGD2AKO cells lacks COX3. A, The indicated cell lines were analyzed by BN and SDS-PAGE and
immunoblotting with the indicated antibodies. B, Affinity-enrichment mass spectrometry (AE-MS) was performed on the NDUFV3FLAG and
control cell lines and significant FLAG interaction partners visualized through a volcano plot. The curved line indicates significance determined
through an FDR-based approach (FDR5%, S0  1). n  3 independent subcultures. C, as for B however, the enrichment was performed on
NDUFV3FLAG/HIGD2AKO relative to the NDUFV3FLAG cell line.
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ate cell lines lacking detectable protein, mitochondrial bio-
chemistry including BN-PAGE, as well as existing and novel
mass-spectrometry based techniques. Although the mamma-
lian proteins were originally identified in a screen for genes
up-regulated upon hypoxic stress (29, 30) the majority of work
has been focused on their yeast homologs Rcf1 and Rcf2
(named for Respiratory complex factors). Three independent
groups reported the functions of Rcf1 and Rcf2 as required for
the formation of the respiratory chain supercomplexes, which
in the yeast S. cerevisiae are comprised of complexes III and
IV (24–26). HIGD2A is thought to be the mammalian ortholog
of Rcf1 and knockdown experiments in mouse myoblasts
were shown to alter the distribution of complex IV-containing
supercomplexes, suggesting the function of HIGD2A in su-
percomplex assembly is conserved from yeast to man (26).
Until now this was the only study to investigate the impact of
HIGD2A loss on mammalian complex IV and supercomplex
assembly, and as a result the function of HIGD2A has largely
been extrapolated from yeast studies. The solution structure
of yeast Rcf1 was recently solved by NMR (68) revealing two
charged transmembrane helices that form salt bridges leading
to formation of a homodimer. Mammalian HIGD2A lacks the
charged membrane helices responsible for Rcf1 dimerization,
suggesting the functions of Rcf1 and HIGD2A may differ.
Despite this point of difference, the results from yeast studies
are generally in agreement with our observations. For exam-
ple, as we found in HIGD2AKO cells, yeast mitochondria lack-
ing Rcf1 still contain the CIII2/IV supercomplex observed us-
ing BN-PAGE (25, 26, 69) (compare with Fig. 3A). Secondly,
using mass-spectrometry we observed turnover of COX6A
and COX6B (Fig. 3B) in HIGD2AKO cells, consistent with the
dissociation of their homologs (Cox13 and Cox12 in yeast) in
yeast Rcf1 knockouts (24, 25). This suggests that like in yeast,
the remaining assembly is still capable of association with
complex III. Finally, we developed a novel pulse-SILAC ap-
proach to assess COX3 biogenesis, finding that accumulation
of newly translated COX3 is reduced in HIGD2AKO cells (Fig.
6C). When we followed the fate of newly translated COX3 in a
chase experiment (Fig. 6D) we found no difference in the rate
of COX3 turnover between HIGD2AKO and control cells.
Taken together, we concluded that HIGD2A is involved in the
early stages of COX3 translation and/or maturation. Our
SILAC based approach has a number of advantages over the
established approach that uses radioactive methionine (65),
including the use of non-radioactive isotopes, the ease of
quantification, and the ability to determine the identity of the
labeled protein directly from peptide sequences rather than
protein migration on SDS-PAGE. On the other hand, disad-
vantages include our inability to quantify the levels of some
SILAC labeled mtDNA encoded proteins from more than a
single peptide, and the technique not being readily adaptable
for monitoring complex assembly via BN-PAGE. Importantly,
our results are consistent with the reduction in steady state
levels of COX3 observed upon deletion of Rcf1 in yeast (25,
28, 69). Indeed, in their original study Strogolova and col-
leagues (25) suggest that Rcf1 may interact with newly trans-
lated COX3 to regulate its association with Cox12 (COX6B)
and complex IV as a means of modulating complex IV activity.
Although our data demonstrates a specific defect in the bio-
genesis of COX3 (Fig. 6C and 6D) it remains unclear if HIGD2A
regulates translation of the subunit or stabilizes its early
stages of biogenesis. The interaction between HIGD2A, COX3
and other complex IV and respiratory chain subunits detected
in our HIGD2AFLAG affinity enrichment experiment (Fig. 6B)
argues for HIGD2A being directly involved in adding COX3 to
the partly assembled complex, whereas the up-regulation of
HIGD2A in patient lymphoblasts with an isolated complex IV
defect arising from impaired translation of mtDNA-encoded
subunits could be taken as an argument for transcriptional
regulation (Fig. 2B). Our previous analysis of fibroblasts from
a patient with a mutation in a subunit of the mitoribosome and
therefore defective translation of all mtDNA-encoded sub-
units, also showed up-regulation of complex IV assembly
factors COX15, SCO2, SURF1 (36) suggesting their up-regu-
lation is a general response to complex IV dysfunction. To
resolve this argument, future studies could investigate the
effect of HIGD2A loss on COX3 mRNA levels and processing
and assess if inhibiting or ablating the function of matrix
proteases can rescue the levels of COX3, and indeed restore
Complex IV function in the HIGD2AKO. Finally, another possi-
bility that warrants investigation is that HIGD2A may work with
mitochondrial inner membrane insertase OXA1 (70) to pro-
mote membrane insertion of COX3. Although OXA1 was not
quantified in our HIGD2AFLAG affinity enrichment, we previ-
ously showed that OXA1 interacts with HIGD2A as well as
several other proteins detected in our experiment (70).
Although we cannot completely exclude the possibility that
HIGD2A can directly regulate complex IV activity, we did not
observe changes in either the levels of HIGD2A or the impact
of its loss on complex IV or supercomplex assembly during
acute or chronic hypoxia as has been suggested for HIGD1A
(supplemental Fig. S2). Our conclusion is that the impact of
HIGD2A on the supercomplex is a pleotropic effect because
of impaired COX3 biogenesis and subsequently defective
complex IV assembly. The intersection of the latter assembly
steps of complexes I, III, and IV with supercomplex formation
(8, 16–18, 20) is also a major factor to be considered in
interpretation of the results from ours and other studies. Our
use of a range of mass-spectrometry based techniques led us
this conclusion. For example, we detected subunits of com-
plexes I, III, and IV as well as assembly factors for complexes
I and IV in our HIGD2AFLAG affinity enrichment and mass-
spectrometry (AE-MS) experiment (Fig. 6B), suggesting that
HIGD2A acts at the stage of both COX3 module integration
into complex IV, and complex IV integration into the super-
complex. Moreover, in our HIGD2AKO cells we observed up-
regulation of complex I and III subunits (Fig. 4A) and used
topographic heatmapping (32, 49) to localize these to the
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interface between complexes I and IV (Fig. 4C). We hypothe-
size this is a mechanism to compensate for their destabiliza-
tion following disruption of their interactions with complex IV
subunits, in agreement with our previous results demonstrat-
ing that loss of the affected complex I subunits leads to total
disassembly of the supercomplex and loss of mitochondrial
respiration (32). Finally, our experiments employing the FLAG
tagged complex I subunit NDUFV3 in the background of
HIGD2AKO demonstrated the presence of a supercomplex
containing subunits of complexes I, III, and IV, but depleted of
COX3 (Fig. 7C). A caveat of this experiment is the equal
enrichment of the other COX3 module subunits in eluates
from both NDUFV3FLAGHIGD2AKO and NDUFV3FLAG cell
lines. One possible explanation for this is that HIGD2AKO cells
contain two populations of supercomplex, one lacking COX3
and one containing a fully assembled supercomplex, which is
consistent with reduced but not absent COX3 biogenesis.
Another possible explanation is the apparent stabilization of
complex IV containing supercomplexes in the HIGD2AKO (e.g.
Fig. 6A) in preference to holo-complex IV, a phenotype we
have previously observed in HEK293T knockouts and patient
cell lines harboring mutations in the complex IV assembly
factor COA6 (53). HIGD2A would not the first assembly factor
suggested to impact supercomplex assembly indirectly (8).
The most well-known example is COX7A2L (SCAFI), which
was originally found within the supercomplex but not holo
complex IV (6). A role of COX7A2L in supercomplex assembly
has been disputed by multiple groups (17–22) and the protein
is now understood to act as a checkpoint for assembly of
complex III into the supercomplex (17). Another example is
UQCC3 (C11orf83), which is an assembly factor suggested to
stabilize the CIII2/IV form of the supercomplex (71). UQCC3
has also been shown to be involved in early complex III
assembly and is found mutated in patients with isolated com-
plex III deficiency (MIM 616097; 72). Importantly, density for
neither HIGD2A, COX7A2L, nor UQCC3 has been identified in
the multiple recent structures representing several different
forms of the mammalian supercomplex assembly (1, 2, 4, 7).
As part of this study we also attempted to validate the role
of HIGD1A in respiratory chain assembly. The function of
mammalian HIGD1A has been studied in more detail than
HIGD2A and the protein has been shown to bind subunits of
the COX1 module (specifically COX4, COX5A) (31). It has been
proposed that during acute hypoxia, the increased amounts
of HIGD1A bind complex IV and induce structural changes
around the heme a active center, increasing complex IV ac-
tivity (31). In agreement, we also showed up-regulation of
HIGD1A protein following 3 h of growth under hypoxic con-
ditions (supplemental Fig. S2) as well as up-regulation of
complex IV subunits, which was previously suggested to be a
mechanism of compensation for the reduced oxygen environ-
ment (55). Consistent with a general function for HIGD1A in
regulation of the respiratory chain during metabolic stress,
Ameri and colleagues (73) showed HIGD1A to be up-regu-
lated upon glucose deprivation, however under these condi-
tions the authors could only show an interaction with subunits
of complex III and not complex IV. In contrast to these studies,
under normoxic conditions, HIGD1A was most recently sug-
gested to associate with an early complex IV assembly inter-
mediate representing the nascent COX1 module (10). In
agreement with this, we detected HIGD1A along with other
complex IV assembly factors and subunits in our HIGD2AFLAG
affinity enrichment experiment (Fig. 6B), suggestive of it being
associated with complex IV during assembly. However, de-
spite small changes in the levels of COX1 module subunits
upon loss of HIGD1A (Fig. 4A, 4D), the lack of a strong
complex IV or supercomplex assembly defect in our
HIGD1AKO (Fig. 3A) argues against its role as an assembly
factor.
In conclusion, although the hypoxia induced domain family
member HIGD2A has previously been implicated in the main-
tenance of respiratory chain supercomplexes, we find it to be
involved in the early biogenesis of mtDNA-encoded COX3.
Loss of HIGD2A leads to turnover of nuclear encoded COX3
partner subunits and accumulation of a supercomplex con-
taining a crippled complex IV. In addition to clarifying previous
reports suggesting HIGD2A involvement in supercomplex as-
sembly, our study identifies HIGD2A as the first assembly
factor required for the biogenesis of the COX3 module of
human complex IV.
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